DiagnoCure licenses lung cancer genes from Genzyme

New York, Nov. 2 - DiagnoCure Inc. said it has licensed worldwide exclusive rights to 40 genes for potential use in detecting lung cancer from Genzyme Corp.

Under the agreement, DiagnoCure will make upfront and milestone payments as well as pay royalties on sales of products.

The Quebec City, Que.-based developer of molecular diagnostics and cell-based assays has granted Genzyme an option to become its partner on commercializing any diagnostic product developed using one or more of the licensed genes.

"This agreement with Genzyme confirms our commitment to becoming a leader in lung cancer detection", said Pierre Desy, DiagnoCure's president and chief executive officer, in a news release.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.